Kisqali Drug Information: Dosage Form, Strength, Administration Method, and Additional Details
In the realm of breast cancer treatment, Kisqali (ribociclib) has emerged as a significant player. This oral tablet, prescribed for HR-positive and HER2-negative breast cancer in adults, comes with a strength of 200 mg [1].
The recommended dosage for both early and advanced forms of the disease is 600 mg (three tablets) per day for 21 consecutive days, followed by a 7-day break. This cycle repeats every 28 days, making Kisqali a treatment meant for long-term use if deemed safe and effective [1][3][5].
Kisqali is typically combined with an aromatase inhibitor (AI) or fulvestrant as endocrine therapy. In pre- or perimenopausal women, a luteinizing hormone-releasing hormone (LHRH) agonist is also required [1]. However, it's worth noting that Kisqali should not be taken in combination with tamoxifen due to potential drug interactions [1].
When it comes to administration, Kisqali should be taken orally, once daily, with or without food. The 21 days on treatment followed by 7 days off pattern repeats in 28-day cycles [1]. If a dose is missed, it should not be taken later in the day. If vomiting occurs after taking Kisqali, no additional dose should be taken that day [3].
It's crucial to remember that the Kisqali dosage may be adjusted based on factors such as kidney or liver function, other drugs taken, side effects, and other medical conditions [1][3].
Missing a dose or overdosing on Kisqali can have potential consequences. If a dose is missed, the patient should take the dose as soon as possible on the same day and then continue with the regular dosing schedule the next day. Patients should not double the dose to make up for the missed one [3].
On the other hand, overdosing on Kisqali can lead to severe symptoms, and if believed to have occurred, immediate medical attention is required. The risk may include increased severity of adverse reactions such as neutropenia, hepatotoxicity, or QT interval prolongation on the ECG [1][3].
For early stage breast cancer, Kisqali is typically taken for a maximum of 3 years. However, the effectiveness of Kisqali can vary from person to person and may not be immediately noticeable [1].
Before starting or stopping any new medications, it's essential to inform your doctor as certain drugs can interact with Kisqali. It's also important to monitor the drug's effectiveness through various tests, as your doctor will do [1].
References:
[1] Novartis. (2025). Kisqali (ribociclib) Summary of Product Characteristics. Retrieved from https://www.novartis.com/sites/www.novartis.com/files/kisqali-european-union-smpc.pdf
[3] Novartis. (2025). Kisqali (ribociclib) Patient Information Leaflet. Retrieved from https://www.novartis.com/sites/www.novartis.com/files/kisqali-european-union-pil.pdf
[5] European Medicines Agency. (2025). Kisqali (ribociclib) European Public Assessment Report. Retrieved from https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali
- Abbvie, the pharmaceutical company, manufactures Kisqali (ribociclib), a significant treatment for HR-positive and HER2-negative breast cancer in adults.
- For both early and advanced stages of breast cancer, the dosage for Kisqali is 600 mg per day, taken orally in 28-day cycles, with a 7-day break.
- Kisqali is often used in combination with an aromatase inhibitor (AI) or fulvestrant, while a luteinizing hormone-releasing hormone (LHRH) agonist is necessary for pre- or perimenopausal women.
- Kisqali should not be taken with tamoxifen due to potential drug interactions, and it should be taken once daily, with or without food.
- In case of missed doses, patients should take the missed dose as soon as possible on the same day and continue with the regular schedule the next day; however, they should not double the dose to make up for missed ones.
- Overdosing on Kisqali can lead to severe symptoms, such as increased severity of adverse reactions like neutropenia, hepatotoxicity, or QT interval prolongation on the ECG, and requires immediate medical attention.
- The effectiveness of Kisqali for early stage breast cancer is typically monitored for a maximum of 3 years, though the drug's impact can vary from person to person and may not be immediately noticeable.
